CareDx, Inc (CDNA) Key Metrics
CDNA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.31B
- Enterprise value
- $2.46B
- P/E (TTM)
- 30.8
- Forward P/E
- 156.2
- PEG ratio
- —
- Price / sales
- 7.2 10-yr median 3.6
- Price / book
- 6.6 10-yr median 3.3
- EV / EBITDA
- 157.8
- Dividend yield
- —
- Beta
- 2.38
CDNA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCDNA valuation Price multiples at each fiscal year-end price.
CDNA returns How much profit the business earns on the capital it uses.
CDNA per-share figures Results divided by the shares outstanding at year-end.
CDNA financial health Debt, liquidity and how easily interest is covered.
CDNA efficiency & capital use Working capital cycle and where the cash goes.
CDNA valuation history
CDNA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CDNA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CDNA cash returned to shareholders
CDNA price vs earnings per share
CDNA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.00B | $1.21B | $645.2M | $608.4M | $2.38B | $3.37B | $909.2M | $896.0M | $171.3M | $44.5M |
| Enterprise value | $852.9M | $980.0M | $444.0M | $354.3M | $2.05B | $3.16B | $876.4M | $831.5M | $188.4M | $51.2M |
| P/E ratio | — | 23.1 | — | — | — | — | — | — | — | — |
| Price / sales | 2.6 | 3.6 | 2.3 | 1.9 | 8.0 | 17.5 | 7.2 | 11.7 | 3.5 | 1.1 |
| Price / book | 3.3 | 3.2 | 2.5 | 1.4 | 5.1 | 12.1 | 9.2 | 9.3 | — | 2.3 |
| Price / free cash flow | 27.8 | 38.4 | — | — | — | 146.0 | — | — | — | — |
| Price / operating cash flow | 23.9 | 31.9 | — | — | — | 100.7 | — | — | — | — |
| EV / sales | 2.2 | 2.9 | 1.6 | 1.1 | 6.9 | 16.4 | 6.9 | 10.9 | 3.9 | 1.3 |
| EV / free cash flow | 23.6 | 31.0 | — | — | — | 137.0 | — | — | — | — |
| Earnings yield | −2.1% | 4.3% | −29.5% | −12.6% | −1.3% | −0.6% | −2.4% | −5.2% | −32.4% | −88.6% |
| Free cash flow yield | 3.6% | 2.6% | −4.3% | −8.1% | −1.7% | 0.7% | −0.7% | −1.3% | −8.5% | −38.3% |
| Dividend yield | — | — | — | — | 0.1% | 0.0% | 0.5% | 3.0% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 8.7% | 0.0% | 4.3% | 0.1% | 0.1% | 0.0% | 0.5% | 3.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $18.84 | $21.41 | $12.00 | $11.41 | $45.48 | $72.45 | $21.57 | $25.14 | $7.34 | $2.70 |
| Per share | ||||||||||
| Revenue per share | $7.13 | $5.90 | $5.21 | $6.03 | $5.67 | $4.13 | $3.01 | $2.15 | $2.07 | $2.46 |
| Earnings per share | −$0.40 | $0.93 | −$3.54 | −$1.44 | −$0.59 | −$0.40 | −$0.52 | −$1.31 | −$2.38 | −$2.39 |
| Operating cash flow per share | $0.79 | $0.67 | −$0.34 | −$0.47 | −$0.37 | $0.72 | −$0.07 | −$0.11 | −$0.61 | −$1.00 |
| Free cash flow per share | $0.68 | $0.56 | −$0.51 | −$0.93 | −$0.76 | $0.50 | −$0.15 | −$0.32 | −$0.62 | −$1.03 |
| Cash per share | $3.33 | $4.60 | $4.38 | $5.50 | $6.67 | $4.83 | $0.91 | $1.81 | $0.72 | $1.05 |
| Book value per share | $5.69 | $6.68 | $4.86 | $8.08 | $8.92 | $5.97 | $2.35 | $2.69 | −$0.26 | $1.18 |
| Tangible book value per share | $4.33 | $5.30 | $3.26 | $6.57 | $7.25 | $4.51 | $0.70 | $1.42 | −$2.20 | −$1.67 |
| Dividends per share | — | — | — | — | $0.04 | $0.03 | $0.10 | $0.75 | $0.00 | $0.00 |
| Capex per share | $0.11 | $0.11 | $0.17 | $0.46 | $0.39 | $0.22 | $0.08 | $0.20 | $0.01 | $0.03 |
| Debt per share | $0.49 | $0.50 | $0.64 | $0.73 | $0.41 | $0.39 | $0.13 | $0.00 | $1.46 | $1.45 |
| Shares outstanding | 53.3M | 56.6M | 53.8M | 53.3M | 52.2M | 46.5M | 42.2M | 35.6M | 23.3M | 16.5M |
| Change in shares outstanding | −5.9% | +5.3% | +0.8% | +2.1% | +12.4% | +10.3% | +18.3% | +52.7% | +41.4% | +39.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −6.3% | 16.4% | −55.0% | −17.1% | −8.2% | −9.9% | −22.5% | −104.1% | — | −161.2% |
| Return on invested capital (ROIC) | −13.3% | 39.3% | −135.6% | −38.7% | −22.4% | −25.9% | −39.7% | −57.9% | −86.2% | −142.0% |
| Return on assets (ROA) | −4.7% | 11.0% | −37.7% | −13.8% | −6.6% | −7.2% | −15.6% | −43.6% | −69.2% | −59.6% |
| Return on tangible assets | −6.3% | 12.7% | −50.0% | −16.6% | −6.4% | −6.2% | −26.7% | −54.7% | −144.4% | −132.6% |
| Free cash flow margin | 9.5% | 9.5% | −9.9% | −15.4% | −13.3% | 12.0% | −4.8% | −14.7% | −30.0% | −42.0% |
| Income quality (OCF / net income) | — | 0.72 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $26.2M | $28.4M | $34.2M | $39.0M | $21.4M | $18.1M | $5.4M | $172,000 | $34.1M | $23.9M |
| Cash & short-term investments | $177.2M | $260.7M | $235.4M | $293.1M | $348.5M | $224.7M | $38.2M | $64.6M | $16.9M | $17.3M |
| Net debt | −$151.0M | −$232.3M | −$201.2M | −$254.1M | −$327.1M | −$206.6M | −$32.8M | −$64.4M | $17.2M | $6.7M |
| Debt / equity | 0.09 | 0.07 | 0.13 | 0.09 | 0.05 | 0.07 | 0.05 | 0.00 | — | 1.23 |
| Debt / assets | 0.06 | 0.06 | 0.07 | 0.07 | 0.04 | 0.05 | 0.04 | 0.00 | 0.41 | 0.31 |
| Current ratio | 2.86 | 3.94 | 4.02 | 5.10 | 5.61 | 3.95 | 2.07 | 4.16 | 0.62 | 0.65 |
| Quick ratio | 2.56 | 3.72 | 3.77 | 4.85 | 5.38 | 3.80 | 1.89 | 3.91 | 0.49 | 0.52 |
| Interest coverage | — | — | — | -20.5 | -3.1 | -83.1 | -6.6 | -4.2 | -3.5 | -20.1 |
| Working capital | $167.3M | $262.5M | $235.6M | $311.9M | $356.1M | $203.9M | $37.1M | $61.6M | −$16.1M | −$14.2M |
| Invested capital | $152.1M | $146.1M | $60.1M | $176.8M | $138.7M | $71.1M | $66.2M | $31.5M | $11.0M | $26.2M |
| Tangible asset value | $230.8M | $299.9M | $175.3M | $350.3M | $378.7M | $209.5M | $29.6M | $50.7M | −$51.1M | −$27.2M |
| Net current asset value | $147.0M | $239.2M | $108.2M | $275.8M | $332.6M | $182.3M | $19.2M | $46.3M | −$62.8M | −$30.3M |
| Graham number | — | $11.81 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $2.11 | $3.64 | $1.45 | $4.51 | $5.76 | $3.55 | $0.16 | $1.11 | −$2.90 | −$2.12 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $2.1M | $1.4M | $4.4M | $26.8M | $0 | $0 |
| Share buybacks (net) | $87.8M | $522,000 | $27.5M | $642,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | 243.0% | 1.7% | — | — | — | 5.9% | — | — | — | — |
| Capex / revenue | 1.6% | 1.9% | 3.3% | 7.6% | 6.8% | 5.4% | 2.6% | 9.5% | 0.4% | 1.4% |
| Capex / operating cash flow | 14.1% | 17.0% | — | — | — | 31.0% | — | — | — | — |
| Capex / depreciation | 0.29 | 0.33 | 0.47 | 1.52 | 1.70 | 1.09 | 0.47 | 1.72 | 0.05 | 0.19 |
| Stock-based compensation / revenue | 9.2% | 19.9% | 17.5% | 14.5% | 12.2% | 12.2% | 17.6% | 9.3% | 3.6% | 4.9% |
| R&D / revenue | 18.8% | 21.7% | 29.2% | 28.1% | 25.8% | 25.5% | 24.2% | 19.0% | 25.6% | 30.5% |
| SG&A / revenue | 55.3% | 37.1% | 71.8% | 61.0% | 51.4% | 53.4% | 59.4% | 57.0% | 65.6% | 78.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 51.5 | 63.2 | 76.4 | 71.5 | 58.1 | 55.7 | 48.6 | 30.4 | 21.7 | 23.1 |
| Days of inventory on hand | 68.4 | 64.9 | 69.2 | 59.2 | 51.0 | 46.3 | 44.0 | 57.9 | 93.9 | 53.8 |
| Days payables outstanding | 26.2 | 34.2 | 40.8 | 37.9 | 43.1 | 43.8 | 41.0 | 44.8 | 55.1 | 40.7 |
| Cash conversion cycle (days) | 93.8 | 93.9 | 104.8 | 92.9 | 66.0 | 58.2 | 51.5 | 43.5 | 60.5 | 36.2 |
| Receivables turnover | 7.08 | 5.77 | 4.78 | 5.10 | 6.28 | 6.55 | 7.52 | 12.01 | 16.78 | 15.83 |
| Payables turnover | 13.95 | 10.67 | 8.94 | 9.64 | 8.47 | 8.33 | 8.90 | 8.14 | 6.62 | 8.97 |
| Inventory turnover | 5.33 | 5.63 | 5.27 | 6.16 | 7.16 | 7.88 | 8.30 | 6.30 | 3.89 | 6.78 |
| Asset turnover | 0.84 | 0.70 | 0.56 | 0.58 | 0.63 | 0.74 | 0.90 | 0.71 | 0.60 | 0.61 |
| Average receivables | $53.6M | $57.8M | $58.7M | $63.0M | $47.2M | $29.3M | $16.9M | $6.4M | $2.9M | $2.6M |
| Average payables | $8.8M | $10.3M | $11.4M | $11.6M | $11.5M | $7.6M | $5.1M | $4.1M | $3.2M | $2.4M |
| Average inventory | $23.1M | $19.5M | $19.4M | $18.2M | $13.6M | $8.0M | $5.5M | $5.2M | $5.5M | $3.1M |
| Intangibles / total assets | 17.5% | 16.0% | 18.4% | 14.8% | 15.4% | 18.5% | 45.7% | 34.6% | 54.0% | 61.2% |
Computed from CDNA's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CDNA valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 30.8 and the forward P/E is 156.2. CareDx earned a return on equity of −6.3% and a return on invested capital of −13.3% in fiscal 2025. It ended the year with $26.2 million of debt and $177.2 million in cash and short-term investments, a net cash position of $151.0 million. It returned $87.8 million to shareholders: $0 in dividends and $87.8 million in share buybacks, 243% of free cash flow. The share count rose 223.0% from 16.5M to 53.3M over 9 years.
See the CDNA income statement, the CDNA chart for price history, or the CDNA stock overview for the latest quote and news.
CDNA key metrics FAQ
What is CareDx's P/E ratio?
CareDx's trailing P/E ratio is 30.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 156.2. At the end of fiscal 2025 it was —.
What is CareDx's return on equity?
CareDx's return on equity (ROE) was −6.3% in fiscal 2025: net income of -$21.4 million on average shareholders' equity of $340.8 million.
What is CareDx's ROIC?
CareDx's return on invested capital was −13.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does CareDx have?
CareDx had total debt of $26.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
Does CareDx buy back its shares?
Yes. CareDx spent $87.8 million on net share repurchases in fiscal 2025 Shares outstanding changed −5.9% over the year, to 53.3M..
What is CareDx's free cash flow yield?
CareDx generated $36.1 million of free cash flow in fiscal 2025, a free cash flow yield of 3.6% on its market value at year-end ($1.0 billion).
What is CareDx's current ratio?
CareDx's current ratio was 2.86 at the end of fiscal 2025: current assets were 2.86 times current liabilities.